STING1 and plasma cell myeloma: To counteract the immune suppression mediated by TGF‐β, a neutralizing antibody together with a STING agonist reduced the immune suppressive effect and suppressed Tregs in an multiple myeloma mouse model.[98] In spontaneous MMTV‐PyMT mammary tumors blocking of TGF‐β restored the activity of DMXAA and therefore the IFN‐induced tumor regression[99] (Figure 4).